{"id":36814,"date":"2026-03-21T09:31:00","date_gmt":"2026-03-21T13:31:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=36814"},"modified":"2026-03-08T14:21:35","modified_gmt":"2026-03-08T18:21:35","slug":"dead-patents-live-money-how-to-turn-abandoned-drug-ip-into-real-revenue","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/dead-patents-live-money-how-to-turn-abandoned-drug-ip-into-real-revenue\/","title":{"rendered":"Dead Patents, Live Money: How to Turn Abandoned Drug IP into Real Revenue"},"content":{"rendered":"\n

Introduction: The Graveyard With a Pulse<\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Every year, thousands of pharmaceutical patents die quietly. No press release. No analyst call. No obituary. The original assignee stops paying maintenance fees, or a prosecution stalls, or a company merger leaves a molecule without a champion. The patent lapses. The lawyers move on.<\/p>\n\n\n\n

What remains is a body of intellectual property that most of the industry ignores \u2014 and a small, disciplined group of operators systematically mines for profit.<\/p>\n\n\n\n

This is not a niche activity. The U.S. Patent and Trademark Office (USPTO) processes tens of thousands of abandoned applications annually across all technology classes, and the pharmaceutical sector accounts for a disproportionate share of that inventory. A 2021 analysis of USPTO data found that roughly 30% of patent applications in the life sciences are abandoned before they reach issuance, and of those that do issue, a significant fraction lapse before their statutory 20-year term expires due to unpaid maintenance fees [1]. The numbers get larger when you include international filings through the European Patent Office (EPO) and the World Intellectual Property Organization (WIPO) Patent Cooperation Treaty (PCT) system.<\/p>\n\n\n\n

Behind each of those lapsed or abandoned filings sits a molecule, a formulation, a manufacturing process, or a method of treatment that someone once thought valuable enough to attempt to protect. The question worth asking is not whether value existed \u2014 it clearly did, at some point. The question is whether the value has genuinely evaporated, or whether the original owner simply ran out of time, money, conviction, or strategic priority.<\/p>\n\n\n\n

The answer, in a meaningful number of cases, is the latter.<\/p>\n\n\n\n

This article maps the full landscape of abandoned pharmaceutical patent monetization: the legal mechanics, the business models, the due diligence frameworks, the valuation methods, and the real-world case studies that prove the opportunity exists. It draws on patent prosecution data, drug development economics, regulatory strategy, and deal structures used by generic manufacturers, specialty pharma companies, academic spinouts, and patent holding entities.<\/p>\n\n\n\n

If you are a business development executive at a mid-size pharma company, an investor evaluating life science IP assets, a licensing professional looking for undervalued compounds, or a legal strategist advising clients on freedom-to-operate questions, the following pages are designed specifically for you.<\/p>\n\n\n\n

\n\n\n\n

Part One: What Patent Abandonment Actually Means<\/h2>\n\n\n\n

The Two Kinds of Abandonment<\/h3>\n\n\n\n

Pharmaceutical patent abandonment comes in two forms, and confusing them is expensive.<\/p>\n\n\n\n

The first is prosecution abandonment<\/strong>, which happens before a patent issues. An applicant files a patent application, receives office actions from the USPTO, and at some point stops responding. The most common reason is failure to reply within the statutory deadline \u2014 typically six months from the mailing date of an office action, extendable with fees. When the deadline passes without a response, the application goes abandoned. The claimed invention never received patent protection.<\/p>\n\n\n\n

The second is post-issuance lapse<\/strong>, which happens after a patent issues. U.S. patents require maintenance fees paid at 3.5, 7.5, and 11.5 years after issuance. The fees are not trivial: as of 2025, the large-entity maintenance fee at the 11.5-year stage is $7,700 [2]. When companies decide a patent is no longer worth carrying, they stop paying. The patent expires early \u2014 before its full 20-year term \u2014 and becomes part of the public domain.<\/p>\n\n\n\n

Each form creates a different type of opportunity. A lapsed issued patent means the claims are known, the prosecution history is accessible, and the scope of what was protected is determinable. A prosecution abandonment means the application disclosed an invention but protection was never secured, which creates a different set of freedom-to-operate questions. Both are exploitable, but the legal analysis differs substantially.<\/p>\n\n\n\n

Strategic Abandonment vs. Accidental Lapse<\/h3>\n\n\n\n

Not every abandoned patent is an accident. Companies sometimes make deliberate decisions to let patents go.<\/p>\n\n\n\n

A large pharmaceutical company running a portfolio of 2,000 active patents across 40 countries spends meaningful resources on maintenance. When a drug candidate fails Phase II, or when a marketed product loses commercial relevance, the rational economic choice is to stop paying for IP that protects nothing of current value. The company’s IP team may conduct an annual “pruning” exercise, cutting patents that no longer align with the company’s commercialization plans.<\/p>\n\n\n\n

The strategic abandonment category is particularly interesting for opportunistic acquirers, because the original company made its decision based on its own commercial roadmap \u2014 not an objective assessment of the compound’s inherent value. A compound that doesn’t fit Pfizer’s therapeutic focus may be exactly what a specialty oncology startup needs. The molecule’s biological activity did not change because Pfizer’s portfolio strategy did.<\/p>\n\n\n\n

Accidental lapses \u2014 where maintenance fees were missed through administrative oversight \u2014 are a different matter. These can sometimes be revived by the original owner (discussed later), which introduces legal risk for anyone who has already begun working under the assumption of freedom to operate.<\/p>\n\n\n\n

What “Public Domain” Actually Means in This Context<\/h3>\n\n\n\n

When a pharmaceutical patent lapses or is abandoned, the claimed invention enters the public domain. In principle, anyone can make, use, sell, or import the claimed product or process without a license from the former patent holder.<\/p>\n\n\n\n

But “public domain” in pharmaceuticals is more complicated than it sounds. The molecule may be free, but the drug is not. To sell a prescription pharmaceutical in the United States, you still need FDA approval. The data that supported the original New Drug Application (NDA) or Biologics License Application (BLA) has its own exclusivity periods independent of patent protection. A compound whose composition-of-matter patent lapsed years ago may still be protected by regulatory data exclusivity that prevents the FDA from relying on the original sponsor’s clinical data to approve a generic version.<\/p>\n\n\n\n

Understanding the layered structure of pharmaceutical protection \u2014 patents, data exclusivity, market exclusivity, orphan drug designations, pediatric exclusivity \u2014 is non-negotiable for anyone trying to exploit abandoned IP. The patent being gone does not automatically mean the commercial barrier is gone.<\/p>\n\n\n\n

This layered structure is exactly why platforms like DrugPatentWatch<\/strong> exist. DrugPatentWatch aggregates and cross-references pharmaceutical patent data, FDA Orange Book listings, exclusivity expirations, and patent litigation history in one place, allowing researchers and business development professionals to quickly map the full protection landscape for a given drug rather than piecing it together from multiple government databases. For anyone serious about abandoned pharmaceutical IP, it is an essential starting point.<\/p>\n\n\n\n

\n\n\n\n

Part Two: The Scale of the Opportunity<\/h2>\n\n\n\n

Patent Abandonment by the Numbers<\/h3>\n\n\n\n

The volume of abandoned pharmaceutical IP is substantial enough to constitute a genuine asset class.<\/p>\n\n\n\n

According to USPTO data, approximately 600,000 patent applications are filed annually across all technology classes. Life sciences and chemistry together account for roughly 15\u201318% of that volume, or approximately 90,000 to 110,000 applications per year [3]. Of those, analyses by IP analytics firms suggest that between 25% and 35% are abandoned at the application stage \u2014 either because the applicant couldn’t overcome prior art rejections, ran out of money, or made a strategic decision to abandon [4].<\/p>\n\n\n\n

At the post-issuance level, the picture is similarly significant. A 2019 study published in the journal Nature Biotechnology<\/em> found that between 2000 and 2015, approximately 10\u201315% of pharmaceutical patents were allowed to lapse before their 20-year term expired, representing thousands of issued patents each year across the U.S., EU, and Japan [5].<\/p>\n\n\n\n

The monetary value implied by those numbers is large. Even a conservative estimate \u2014 assuming that 1% of abandoned pharmaceutical patents contain commercially viable IP \u2014 generates a pool of hundreds of assets annually. Given that a single successful drug repositioning program can generate hundreds of millions of dollars in revenue, the expected value of that pool is material.<\/p>\n\n\n\n

Which Therapeutic Areas Have the Highest Abandonment Rates?<\/h3>\n\n\n\n

Therapeutic areas with high abandonment rates tend to cluster around two poles: scientific difficulty and commercial uncertainty.<\/p>\n\n\n\n

Neurological and psychiatric drug development has historically produced high abandonment rates, driven by the notoriously difficult blood-brain barrier penetration challenge, complex trial endpoint selection, and the high Phase II failure rate (estimated at 70\u201380% for CNS drugs, compared to 60\u201365% for oncology) [6]. The result is a large inventory of abandoned CNS patents covering molecules with documented pharmacological activity that never made it through clinical development.<\/p>\n\n\n\n

Oncology presents a different dynamic. Development activity is high, but so is patent volume \u2014 meaning the field generates large absolute numbers of abandonments even if the percentage rate is lower. Oncology also benefits from the regulatory advantages of accelerated approval pathways, which can reduce the clinical investment required to bring a repositioned asset to approval.<\/p>\n\n\n\n

Infectious disease, antibiotic development in particular, has near-catastrophic abandonment rates. The economics of antibiotics \u2014 limited dosing duration, price ceilings in most markets, concerns about antimicrobial resistance driving restrictions on use \u2014 have led virtually every major pharmaceutical company to exit the antibiotic pipeline. The abandoned IP inventory in this space is enormous, and the public health case for exploitation is arguably stronger than in any other therapeutic area.<\/p>\n\n\n\n

Rare diseases (those affecting fewer than 200,000 patients in the U.S. under the Orphan Drug Act) occupy their own category. Companies sometimes abandon rare disease programs not because the science failed but because they lacked the commercial infrastructure to develop orphan-designated assets efficiently. Those programs, once abandoned, become candidates for orphan drug repositioning by entities specifically built to exploit the FDA’s orphan drug incentives.<\/p>\n\n\n\n

The Geographic Dimension: Think Beyond the USPTO<\/h3>\n\n\n\n

Most opportunistic patent analysis focuses on U.S. filings because the USPTO database is the most accessible and the U.S. pharmaceutical market is the most lucrative. That focus misses a substantial secondary opportunity.<\/p>\n\n\n\n

Many pharmaceutical patents are filed through the PCT system, which allows a single international application to enter the national phase in dozens of countries. Large companies routinely file PCT applications but then selectively abandon them in lower-priority markets \u2014 South Korea, Brazil, India, Mexico, Southeast Asian countries \u2014 either because the local market doesn’t justify the prosecution costs, or because the drug was never intended for those markets.<\/p>\n\n\n\n

Those abandoned national-phase patents create freedom-to-operate specifically in those markets. A company manufacturing a generic version of a compound in a country where the patent was never prosecuted or was abandoned can export to third-country markets where the patent is similarly absent. This geographic arbitrage is the economic foundation of much of the developing-world generic pharmaceutical industry, and it remains available to well-informed operators.<\/p>\n\n\n\n

\n\n\n\n

Part Three: Why Companies Walk Away<\/h2>\n\n\n\n

Understanding why a patent was abandoned matters as much as knowing that it was. The reason for abandonment is a signal about the nature of the remaining opportunity.<\/p>\n\n\n\n

Pipeline Reprioritization<\/h3>\n\n\n\n

The pharmaceutical industry runs on portfolio prioritization. Large companies managing hundreds of programs in simultaneous development must constantly make allocation decisions about scientific, clinical, and financial resources. A molecule that is scientifically promising but not competitive enough to win against similar drugs already in development \u2014 what the industry calls the “fifth-to-market problem” \u2014 will often be deprioritized and eventually abandoned, even if it works.<\/p>\n\n\n\n

The opportunity here is repositioning. A compound abandoned because it had no competitive advantage for its originally targeted indication may have unique value for a different indication. The classical example in this category is sildenafil, originally developed by Pfizer as a treatment for angina and hypertension. The cardiovascular program was abandoned, but the drug went on to become one of the best-selling pharmaceuticals in history as Viagra. The repositioning wasn’t accidental \u2014 it followed from clinical data showing an unexpected pharmacological effect \u2014 but the principle illustrates how commercial irrelevance in one context doesn’t preclude value in another.<\/p>\n\n\n\n

Capital Constraints<\/h3>\n\n\n\n

Early-stage companies account for a large share of pharmaceutical patent filings, and early-stage companies run out of money. A startup that files a composition-of-matter patent on a novel kinase inhibitor but can’t raise a Series A will eventually be forced to stop paying prosecution fees and maintenance fees. The patent lapses not because the science failed but because the business did.<\/p>\n\n\n\n

This category creates some of the cleanest acquisition opportunities. The original inventors are often identifiable, sometimes still in academia, and frequently willing to discuss either a licensing arrangement or an outright sale of the patent rights. In some cases, the failed startup retained legal title to the IP even after the company itself wound down, and former management teams can be located and engaged directly.<\/p>\n\n\n\n

Clinical Failure Doesn’t Mean IP Failure<\/h3>\n\n\n\n

Clinical failure is the most common reason for abandonment, but it requires careful interpretation. A compound that failed a Phase II trial for one indication may have failed for reasons that are specific to that trial design, patient population, dosing regimen, or endpoint selection \u2014 not because the molecule has no biological activity.<\/p>\n\n\n\n

The clinical literature is full of compounds that failed their first large trial and were later shown to work in a different context. Thalidomide is the most extreme example: a compound withdrawn from the market because of catastrophic teratogenic effects was later approved as a treatment for multiple myeloma and erythema nodosum leprosum. The IP originally covering thalidomide had long since expired, but the principles that allowed its return \u2014 rescue by new indication, new patient population, new safety risk management \u2014 apply equally to compounds where IP abandonment has occurred for clinical failure reasons.<\/p>\n\n\n\n

The key analytical question is: did the molecule fail to achieve the intended biological effect, or did it achieve the intended effect but fail on clinical trial design, safety in the tested population, or commercial feasibility in the tested indication? The first type of failure is harder to overcome. The second is not a failure of the science at all.<\/p>\n\n\n\n

Merger and Acquisition Casualties<\/h3>\n\n\n\n

Large pharmaceutical M&A transactions routinely produce orphaned patent portfolios. When AstraZeneca acquires a biotech, or when two large pharma companies merge, the combined entity inherits overlapping programs. Internal competition means that some programs will be killed regardless of their scientific merit. IP associated with those killed programs may be sold, licensed out, or simply abandoned.<\/p>\n\n\n\n

M&A orphans are interesting because they have often reached relatively advanced stages of development. A compound killed in Phase II or early Phase III by a newly merged company that inherited a competing internal program may have substantial clinical data behind it \u2014 data that is publicly available in clinical trial registrations and publications \u2014 without active patent protection if the IP was abandoned in the merger consolidation.<\/p>\n\n\n\n

\n\n\n\n

Part Four: The Legal Framework You Must Understand<\/h2>\n\n\n\n

USPTO Abandonment Status vs. True Expiration<\/h3>\n\n\n\n

The first thing any analyst must distinguish is whether a patent is abandoned (never issued, or voluntarily given up) versus expired (ran its 20-year course). The distinction is not merely academic.<\/p>\n\n\n\n

A patent application that was abandoned before issuance did not generate an issued patent. Therefore, it generated no patent rights that could be infringed. The disclosed invention is in the public domain via the published application (assuming it was published, which most applications are under the American Inventors Protection Act 18-month publication requirement). The claims, however, were never granted. Anyone can freely use the disclosed invention.<\/p>\n\n\n\n

An issued patent that was allowed to expire due to nonpayment of maintenance fees also places the claimed invention in the public domain \u2014 but the issued claims establish a clear record of what was protected and for how long. That record is useful for mapping what competitors could and could not have done during the patent’s active life, and for tracing continuation and divisional applications that may still be active.<\/p>\n\n\n\n

The USPTO Patent Center (formerly Patent Application Information Retrieval, or PAIR) is the primary source for prosecution status information. The system is publicly accessible and shows the full prosecution history \u2014 every office action, every response, every fee payment or nonpayment \u2014 for any application or issued patent in the system.<\/p>\n\n\n\n

Intervening Rights<\/h3>\n\n\n\n

“Intervening rights” is a doctrine that applies when a patent that lapsed for nonpayment is subsequently revived by the original owner (discussed more below). If a third party began manufacturing and selling a product that would have infringed the patent during the gap between lapse and revival, the patent owner’s rights against that third party are limited.<\/p>\n\n\n\n

Specifically, 35 U.S.C. \u00a7 41(c)(2) provides that a revived patent cannot be enforced against a party who made, purchased, or used the patented product during the period between lapse and revival, or who made substantial preparations to do so [7]. The practical implication is that if you identify an abandoned patent and invest significantly in product development, you may retain the right to continue making and selling the product even if the patent is revived, though you cannot expand that activity.<\/p>\n\n\n\n

Intervening rights reduce the risk of revival but do not eliminate it entirely. They are a legal safety net, not a guarantee.<\/p>\n\n\n\n

Freedom to Operate After Abandonment<\/h3>\n\n\n\n

An abandoned patent does not exist in isolation. Any molecule of pharmaceutical interest is likely to be surrounded by a family of related patents and applications. A composition-of-matter patent may have lapsed, but method-of-treatment patents or formulation patents filed by the same company or third parties may still be active. Process patents covering the synthesis route may belong to a different company entirely.<\/p>\n\n\n\n

A thorough freedom-to-operate (FTO) analysis is mandatory before any serious investment in exploiting an abandoned patent. The FTO analysis asks: taking the abandoned patent’s disclosed technology as a starting point, what active patents cover the commercial activities I intend to pursue (making, using, selling, importing)? Who owns those patents? What licenses or design-arounds are needed?<\/p>\n\n\n\n

Skipping the FTO analysis to save legal fees is a false economy. The cost of a thorough FTO analysis \u2014 typically $10,000 to $50,000 depending on the complexity of the technology and the number of potentially relevant patent families \u2014 is trivial compared to the cost of a patent infringement suit discovered after commercial launch.<\/p>\n\n\n\n

Revival Possibilities and Their Threat<\/h3>\n\n\n\n

A lapsed patent can sometimes be revived. Under 37 C.F.R. \u00a7 1.137, an applicant can petition to revive an abandoned application if the abandonment was unintentional [8]. The petitioner must show that the delay in responding (or paying maintenance fees) was unintentional \u2014 not that it was excusable for some non-negligence reason, but that there was no intention to abandon.<\/p>\n\n\n\n

The standard is relatively permissive. Companies have successfully revived patents after multi-year lapses. The revival requires payment of all overdue fees plus a petition fee, and the USPTO has broad discretion to grant or deny.<\/p>\n\n\n\n

The revival risk is not hypothetical. There are documented cases of companies reviving abandoned pharmaceutical patents after discovering that a competitor was exploiting the lapsed IP. The revival does not necessarily invalidate the competitor’s intervening activities, but it complicates the legal picture and can trigger infringement litigation.<\/p>\n\n\n\n

The practical mitigation is to conduct a revival risk assessment as part of due diligence: How old is the abandonment? Is the original assignee still an operating entity? Does the original assignee have any commercial reason to revive (e.g., a competitor has appeared with a similar product)? Has the original assignee filed continuation applications that might cover the same subject matter?<\/p>\n\n\n\n

\n\n\n\n

Part Five: Five Business Models Built on Abandoned Patents<\/h2>\n\n\n\n

The architecture of an abandoned patent monetization strategy depends on whether you want to develop, license, aggregate, or simply clear the field. Here are the five models that generate real returns.<\/p>\n\n\n\n

1. Generic Drug Development<\/h3>\n\n\n\n

The most direct model: use abandoned composition-of-matter patents to manufacture and sell a generic version of a drug without infestation by the original IP. This is the economic engine of the generic pharmaceutical industry.<\/p>\n\n\n\n

The generic model requires that you navigate not only the patent layer but also the regulatory data exclusivity layer. Under the Hatch-Waxman Act, the FDA can rely on a reference listed drug’s (RLD) clinical data to support a generic approval via the Abbreviated New Drug Application (ANDA) pathway \u2014 but only after the applicable exclusivity periods have expired [9]. A New Chemical Entity (NCE) gets five years of data exclusivity. A new clinical investigation exclusivity can add three more years. An orphan designation adds seven.<\/p>\n\n\n\n

Once exclusivity expires, the ANDA pathway is open. If the composition-of-matter patent is also gone, the generic manufacturer faces no patent challenge and no data exclusivity barrier. The path to market is primarily technical and regulatory: bioequivalence studies, manufacturing compliance, and ANDA review.<\/p>\n\n\n\n

The profit margins on generics that entered an uncontested market after full exclusivity expiration can be significant, particularly in the early months before additional generic entrants appear. Market modeling from IQVIA and others has consistently shown that the first generic entrant captures a disproportionate share of the market in the initial period, often pricing at 80\u201390% of the branded price before subsequent entrants force prices down [10].<\/p>\n\n\n\n

2. New Chemical Entity Licensing (Drug Repositioning)<\/h3>\n\n\n\n

The repositioning model requires more investment than generic development but offers substantially higher commercial upside. The core idea: take a compound whose original patents have lapsed or been abandoned, identify a new indication where the compound may work, file new patents covering the new use, and either develop the drug yourself or license the new indication-specific IP to a pharmaceutical company.<\/p>\n\n\n\n

The new IP created by a successful repositioning program \u2014 use patents, dosing patents, formulation patents covering the new indication \u2014 can restore robust patent protection to a molecule that was previously unprotected. A company that successfully repositions an off-patent compound and obtains FDA approval for the new indication under a Section 505(b)(2) NDA may also qualify for new data exclusivity periods under the new indication, providing regulatory protection even as the original composition-of-matter patent remains in the public domain.<\/p>\n\n\n\n

This model requires genuine scientific and regulatory expertise. Identifying a new indication requires understanding the compound’s mechanism of action, reviewing the clinical literature for signals in the desired therapeutic area, and designing early-stage clinical studies to generate proof-of-concept data. It is not a purely financial exercise.<\/p>\n\n\n\n

The financial payoff from successful repositioning, however, is large. Studies by the Tufts Center for the Study of Drug Development estimate the average cost of repositioning an existing compound at $300 million to $500 million \u2014 roughly half to one-third the cost of developing a new chemical entity from scratch \u2014 with similar revenue potential for successful programs [11].<\/p>\n\n\n\n

3. Research Tool Commercialization<\/h3>\n\n\n\n

Not every abandoned pharmaceutical patent describes a drug. Many describe research tools: assay methods, screening platforms, biomarker identification methods, animal models, and cell-based platforms used in drug discovery. These research tool patents can be highly valuable to academic institutions, CROs, and pharmaceutical companies even after commercial drug development around the underlying compound has been abandoned.<\/p>\n\n\n\n

A company that abandons a patent portfolio because it exited a particular therapeutic area may leave behind research tool IP that is essential to anyone working in that space. That IP can be acquired inexpensively \u2014 often for the cost of filing the petition to revive a lapsed application, plus a modest purchase price from a company that considers the assets non-core \u2014 and then commercialized through a licensing program targeting the research community.<\/p>\n\n\n\n

The research tool licensing model is asset-light. You don’t need a laboratory or regulatory infrastructure. You need lawyers to document the acquisition, a licensing team to approach potential users, and an enforcement strategy for non-payers.<\/p>\n\n\n\n

4. Defensive Patent Acquisition (Freedom-to-Operate Shield)<\/h3>\n\n\n\n

This model is less about generating revenue directly and more about eliminating liability. A company developing a product in a space with complex IP history may identify abandoned patents that could theoretically be revived and asserted against it. Acquiring those patents \u2014 even if the intent is never to assert them \u2014 eliminates the revival risk and creates an IP shield.<\/p>\n\n\n\n

The defensive acquisition model is common in large-company strategic IP planning. If a company can acquire a lapsed patent for $50,000 that would cost $5 million to defend against in litigation if revived by a non-practicing entity (NPE), the math is straightforward. Patent brokerage firms and technology transfer offices at universities often hold these types of assets and will sell them for relatively low prices to acquirers who present a credible use case.<\/p>\n\n\n\n

5. Patent Aggregation and NPE Licensing Programs<\/h3>\n\n\n\n

The NPE (non-practicing entity) model involves acquiring abandoned pharmaceutical patents not for drug development purposes but for licensing revenue. The strategy requires identifying patents with broad claims that cover commercial activities currently being practiced by operating companies \u2014 whether they know it or not \u2014 and asserting licensing demands.<\/p>\n\n\n\n

This model is controversial and has faced significant legal headwinds since the Alice Corp. v. CLS Bank International<\/em> Supreme Court decision [12] and subsequent Federal Circuit case law limiting patent eligibility for certain categories of inventions. In pharmaceuticals, where method-of-treatment claims have faced Section 101 eligibility challenges, the NPE model requires careful claim selection.<\/p>\n\n\n\n

That said, legitimate licensing programs built on genuinely valuable abandoned IP remain viable. A company that acquires manufacturing process patents abandoned by a large pharma company and licenses them to generics manufacturers operating in markets where those processes are economically essential is performing a value-creating function, not simply a rent-extraction exercise.<\/p>\n\n\n\n

\n\n\n\n

Part Six: How to Find Abandoned Patents Worth Pursuing<\/h2>\n\n\n\n

Where the Data Lives<\/h3>\n\n\n\n

The primary sources for abandoned patent data are the USPTO Patent Center, the EPO’s Espacenet database, and WIPO’s PatentScope system. Each covers different jurisdictions. The USPTO system tracks U.S. prosecution history; Espacenet covers European filings and has good coverage of national filings from EPO member states; PatentScope covers PCT applications.<\/p>\n\n\n\n

The challenge is that these systems are designed for patent professionals, not business strategists. They require familiarity with classification systems (CPC and IPC codes), search syntax, and prosecution status indicators. Pulling actionable intelligence from raw patent database searches requires either significant internal expertise or access to purpose-built analytics tools.<\/p>\n\n\n\n

DrugPatentWatch<\/strong> occupies a particularly useful position in this research ecosystem for pharmaceutical-specific analysis. The platform aggregates FDA Orange Book data, patent expiration information, maintenance fee status, and patent litigation records in a single interface designed for pharmaceutical business development professionals. When you’re trying to determine not just whether a composition-of-matter patent has lapsed but whether there are still active formulation, method-of-treatment, or Orange Book-listed patents protecting the drug, DrugPatentWatch’s cross-referenced database structure saves hours of manual research.<\/p>\n\n\n\n

For initial landscape scanning, a practical workflow combines USPTO Patent Center searches on specific chemical entities or therapeutic targets with DrugPatentWatch’s drug-by-drug profile pages, which show the full IP and regulatory exclusivity picture for approved drugs. That combination lets you quickly identify drugs that are commercially significant, whose core patents have lapsed, and whose regulatory exclusivity may be expiring or already expired.<\/p>\n\n\n\n

Systematic Search Strategies<\/h3>\n\n\n\n

Random browsing of patent databases is inefficient. Effective abandoned patent prospecting uses systematic criteria to filter the universe down to actionable targets.<\/p>\n\n\n\n

The first filter is therapeutic relevance. Start with a defined therapeutic area or target class (e.g., kinase inhibitors, GPCRs, ion channel modulators) and use IPC or CPC classification codes to retrieve all patent filings in that space. Run the result set through a status filter to identify abandoned or lapsed patents. This gives you a population of abandoned patents in your area of interest.<\/p>\n\n\n\n

The second filter is assignee analysis. Which companies have the most abandoned patents in this space? Companies undergoing restructuring, companies that completed therapeutic-area divestitures, or startups that failed are the most productive sources. Cross-reference with EDGAR filings (for public companies), business registrations, and news archives to understand why the company stopped prosecuting.<\/p>\n\n\n\n

The third filter is claims quality. Not all patent claims are created equal. Broad composition-of-matter claims covering a class of chemical structures are more valuable than narrow method claims tied to a specific indication with limited commercial scope. An initial claims review \u2014 which can be done by a patent agent in a few hours \u2014 will quickly separate the structurally interesting abandonments from the marginal ones.<\/p>\n\n\n\n

The fourth filter is competitive intelligence. Is anyone else currently working with this compound? Check ClinicalTrials.gov for active or recently completed trials. Check the FDA Orange Book for current listings. Check the scientific literature for recent publications. A compound with active clinical interest but no IP coverage is a high-priority target.<\/p>\n\n\n\n

Red Flags That Make Abandoned Patents Worthless<\/h3>\n\n\n\n

Some abandoned patents are abandoned for very good reasons. The following signals suggest the opportunity is either legally compromised or commercially irrelevant:<\/p>\n\n\n\n

Dense prior art.<\/strong> If the abandoned patent was narrowly claimed because of blocking prior art, and that prior art is still in the public domain, the freedom you gain from the abandonment may be illusory. There’s no point acquiring freedom to operate in a space you couldn’t have blocked anyway.<\/p>\n\n\n\n

Toxicity data.<\/strong> If the compound was abandoned because of documented in vivo toxicity findings \u2014 particularly organ toxicity, genotoxicity, or carcinogenicity signals in preclinical studies \u2014 the FDA will require extensive safety data before any new clinical program. The regulatory cost of overcoming documented toxicity can exceed the cost of developing a new compound.<\/p>\n\n\n\n

Active continuation families.<\/strong> The original assignee may have filed continuation or continuation-in-part applications after abandoning the parent patent. Those continuations may be active and may cover the same subject matter under different claim language. Always check for related applications before concluding that the IP space is clear.<\/p>\n\n\n\n

Sovereign abandonment with revival rights.<\/strong> Some international jurisdictions allow lapsed patents to be reinstated more liberally than the U.S. system. In European countries, for example, a patent that lapsed for nonpayment can often be reinstated within 12 months of the fee due date. Always verify the revival window in each relevant jurisdiction.<\/p>\n\n\n\n

\n\n\n\n

Part Seven: Due Diligence \u2014 What to Check Before You Act<\/h2>\n\n\n\n

The File Wrapper Is Your Primary Source<\/h3>\n\n\n\n

The prosecution history of a patent \u2014 the complete record of office actions, applicant responses, examiner interviews, claim amendments, and legal arguments \u2014 is called the “file wrapper” or “file history.” For issued patents and abandoned applications in the U.S., the file wrapper is publicly accessible through the USPTO Patent Center.<\/p>\n\n\n\n

Reading the file wrapper is essential for two reasons. First, it tells you what the claims actually cover. The doctrine of prosecution history estoppel means that claim scope can be narrowed by arguments made during prosecution. A composition-of-matter claim that appears broad on its face may have been narrowed by a limiting argument made to overcome a prior art rejection. If the argument conceded that the claimed compound doesn’t include certain structural variations, competitors making those variations may be free to act even without abandonment.<\/p>\n\n\n\n

Second, the file wrapper tells you why the patent was abandoned. Was it an office action response failure (possibly administrative)? Did the examiner issue a final rejection on prior art grounds that the applicant couldn’t overcome? Did the applicant receive a notice of allowance and then fail to pay the issue fee? Each scenario has different implications for the strength of the underlying IP and the risk of revival.<\/p>\n\n\n\n

Prior Art Density Analysis<\/h3>\n\n\n\n

Before investing in any abandoned pharmaceutical patent, map the prior art landscape. Prior art includes all patents, publications, public uses, and on-sale activity predating the filing date of the application you’re analyzing.<\/p>\n\n\n\n

High prior art density means that even if you could enforce the abandoned patent’s claims against someone, those claims would be vulnerable to invalidity challenges. In inter partes review (IPR) proceedings at the USPTO, patents are challenged and invalidated at rates that have consistently exceeded 60% of petitioned claims since IPR was introduced by the America Invents Act in 2012 [13]. A patent that sits in a crowded prior art field is a weak patent, regardless of its abandonment status.<\/p>\n\n\n\n

Low prior art density \u2014 the “clear field” situation where a compound or method was genuinely novel at the time of filing \u2014 creates stronger rights if you file new patents on new uses or improvements. It also means that a competitor trying to invalidate any new IP you develop will have a harder time finding prior art to rely on.<\/p>\n\n\n\n

Freedom-to-Operate Assessment<\/h3>\n\n\n\n

The FTO analysis maps active third-party patents against your intended commercial activities. It is distinct from the abandoned patent acquisition analysis: you’re not asking whether the abandoned patent is valid and enforceable, you’re asking whether anything else stops you from doing what you want to do.<\/p>\n\n\n\n

A pharmaceutical FTO typically covers:<\/p>\n\n\n\n

Composition-of-matter claims covering the compound itself or structural analogs. Method-of-treatment claims covering the intended indication. Formulation patents covering the dosage form you intend to use. Manufacturing process patents covering the synthesis route. Device patents if the drug is administered via a proprietary device.<\/p>\n\n\n\n

Each category requires separate analysis because different companies may own patents in each category. A compound free from composition-of-matter claims may still be encumbered by a competitor’s formulation patent covering the extended-release technology needed to make it commercially viable.<\/p>\n\n\n\n

Related Patent Families: The Hidden Threat<\/h3>\n\n\n\n

The most common due diligence failure in abandoned patent analysis is incomplete family search. A patent “family” encompasses all applications that share a common priority date \u2014 typically the original provisional application. The family may include continuations, divisionals, continuations-in-part (CIPs), and foreign counterparts.<\/p>\n\n\n\n

When a parent patent is abandoned, continuation applications claiming the same or similar subject matter may still be active. The continuation inherits the parent’s filing date for priority purposes, but it can have its own 20-year term running from its own filing date. Depending on how many continuations were filed and when, you could be looking at a patent family with active members expiring decades after the abandoned parent.<\/p>\n\n\n\n

Tools like Derwent Innovation, PatSnap, and Innography automatically identify patent families and show which members are active and which are abandoned. Conducting a family analysis is a non-negotiable step \u2014 it takes a day, costs a few thousand dollars in analyst time, and prevents the kind of errors that result in massive post-investment litigation risk.<\/p>\n\n\n\n

\n\n\n\n

Part Eight: Valuation Models for Abandoned Drug Patents<\/h2>\n\n\n\n

The Income Approach<\/h3>\n\n\n\n

The income approach values a patent based on the future cash flows it is expected to generate, discounted to present value. For a pharmaceutical patent, those cash flows might come from licensing revenue, from the commercial sale of a product enabled by the patent, or from the avoidance of royalty payments that would otherwise be owed to a licensor.<\/p>\n\n\n\n

The income approach requires building a revenue model for the underlying drug. That model draws on market size data for the target indication, penetration assumptions based on competitive landscape, pricing assumptions based on analogous drugs, and probability-of-success estimates for the remaining development stages.<\/p>\n\n\n\n

Risk-adjusted net present value (rNPV) is the standard framework in pharmaceutical deal valuation. The rNPV takes each future cash flow, adjusts it for the probability of reaching that stage (Phase I success rate, Phase II success rate, Phase III success rate, regulatory approval rate), and discounts it to present value at an appropriate rate (typically 10\u201315% for pharmaceutical assets) [14]. The result is a probability-weighted present value that accounts for the high failure rate inherent in drug development.<\/p>\n\n\n\n

For abandoned patents where development has already progressed to some stage, the rNPV benefits from existing data. A compound with completed Phase I safety data has a higher probability of ultimate success than a preclinical compound, and the rNPV calculation should reflect that.<\/p>\n\n\n\n

Comparable Transaction Analysis<\/h3>\n\n\n\n

The comparable transaction method values a patent by reference to prices paid in recent transactions involving similar assets. The pharmaceutical IP market produces a rich set of comparable data: licensing deals with royalty rates, milestone structures, and upfront fees are disclosed in SEC filings (8-K reports) by public companies; M&A transactions involving drug candidates are regularly reported by industry intelligence services like Evaluate Pharma, BioPharma Catalyst, and GlobalData.<\/p>\n\n\n\n

Royalty rates in pharmaceutical licensing are empirically documented across therapeutic areas, development stages, and asset types. The “25% rule” \u2014 which holds that royalties should represent approximately 25% of pre-tax operating profits \u2014 is widely cited but imprecise; actual royalty rates vary from less than 1% to more than 15% of net sales depending on the specifics of the asset and the deal [15]. For compounds with strong composition-of-matter protection, double-digit royalties on net sales are achievable in deals with large commercial partners.<\/p>\n\n\n\n

For abandoned patents where the asset is being acquired rather than licensed, the transaction database on patent auctions and brokered deals \u2014 maintained by firms like IP Offerings, Ocean Tomo, and AST \u2014 provides reference points for single-patent and small-portfolio acquisitions.<\/p>\n\n\n\n

The Risk-Adjusted Framework in Practice<\/h3>\n\n\n\n

A simplified example illustrates the mechanics:<\/p>\n\n\n\n

Assume you have identified an abandoned composition-of-matter patent covering a kinase inhibitor that failed a Phase II trial for non-small cell lung cancer (NSCLC) in 2018. The patent lapsed in 2022 when the original sponsor failed to pay the 7.5-year maintenance fee. ClinicalTrials.gov shows no active trials. DrugPatentWatch confirms no active Orange Book listings. A preliminary FTO analysis shows no blocking third-party patents on the compound itself, though a third-party has a formulation patent on a sustained-release formulation that would need to be designed around.<\/p>\n\n\n\n

You believe the compound may work in a different NSCLC subtype (based on a published biomarker study from 2021) and you want to estimate the value of filing new use patents and conducting a proof-of-concept Phase II trial.<\/p>\n\n\n\n

Revenue model: NSCLC subtype market of approximately 30,000 patients in the U.S. Drug priced at $12,000\/month (consistent with oral kinase inhibitors in this space). Market penetration reaching 20% at peak. Revenue at peak = 30,000 x 20% x $144,000\/year = $864 million.<\/p>\n\n\n\n

Risk adjustment: probability of Phase II success (approximately 45% for oncology) x probability of Phase III success (approximately 55%) x probability of approval (approximately 85%) = combined probability of approximately 21% [16].<\/p>\n\n\n\n

rNPV: $864 million peak revenue x 21% success probability, with a drug patent life of approximately 12 years from projected approval, discounted at 12% = approximately $180\u2013220 million rNPV at peak revenue year, discounted back to today.<\/p>\n\n\n\n

The value of acquiring the abandoned patent and filing use patents around it: some fraction of that $180\u2013220 million, reflecting the company’s share of the value at deal (typically 30\u201350% for a development-stage asset brought in by a large pharmaceutical partner).<\/p>\n\n\n\n

Even a back-of-the-envelope calculation suggests acquisition investment in the hundreds of thousands to low millions of dollars is justified for the right asset.<\/p>\n\n\n\n

\n\n\n\n

Part Nine: Case Studies in Abandoned Patent Monetization<\/h2>\n\n\n\n

<blockquote> “The average cost to bring a drug from discovery through FDA approval has reached $2.6 billion when accounting for the cost of failures.” \u2014 Tufts Center for the Study of Drug Development, 2016 [17] <\/blockquote><\/p>\n\n\n\n

That $2.6 billion figure explains why drug repositioning from abandoned IP is so economically attractive: if a compound has already cleared preclinical development, Phase I safety assessment, and even Phase II efficacy trials, the remaining development cost and risk profile are substantially reduced compared to starting from scratch.<\/p>\n\n\n\n

Thalidomide: The Most Dramatic Resurrection in Pharmaceutical History<\/h3>\n\n\n\n

Thalidomide was first marketed in the late 1950s as a sedative and treatment for morning sickness. Withdrawn from most markets by 1961 after causing severe limb deformities in children born to women who took the drug during pregnancy, it became a symbol of pharmaceutical catastrophe. Its original patents had long since expired.<\/p>\n\n\n\n

Forty years later, thalidomide was approved by the FDA in 1998 under the brand name Thalomid for the treatment of erythema nodosum leprosum, a complication of leprosy. In 2006, it received approval for multiple myeloma in combination with dexamethasone. Celgene (now part of Bristol-Myers Squibb) built a multi-billion-dollar business on the thalidomide analog framework, developing lenalidomide (Revlimid) and pomalidomide (Pomalyst) as successors with improved safety profiles and expanded indications.<\/p>\n\n\n\n

The thalidomide story demonstrates that even deeply troubled abandoned compounds \u2014 one would struggle to imagine an asset more apparently toxic to commercial development than thalidomide \u2014 can generate substantial value when the right biological activity is matched with the right indication and patient population.<\/p>\n\n\n\n

The lesson is not that toxic compounds should be routinely revisited. It is that the original commercial failure does not determine the ultimate value of a chemical entity. The compound’s biology doesn’t change. What changes is the scientific framework for understanding it and the regulatory framework for managing its risks.<\/p>\n\n\n\n

Sildenafil: Accidental Repositioning as Proof of Concept<\/h3>\n\n\n\n

The sildenafil story is the most frequently cited example of drug repositioning, and it bears examination here because the underlying mechanism \u2014 abandoned indication, unexpected new use \u2014 mirrors exactly what deliberate abandoned patent exploitation attempts.<\/p>\n\n\n\n

Pfizer’s researchers were studying sildenafil as a treatment for angina and hypertension in the early 1990s. Clinical trials showed modest cardiovascular efficacy and an unexpected side effect: penile erection. The angina program was discontinued. The compound was not abandoned \u2014 Pfizer retained it and pursued the unexpected effect as a new indication \u2014 but the logic is instructive.<\/p>\n\n\n\n

Had Pfizer not noticed the side effect, or had the compound been at an earlier stage where the clinical signal wasn’t captured, sildenafil might have been abandoned as a failed cardiovascular drug. The composition-of-matter patent, filed in 1989, would have entered the public domain. Any pharmaceutical company that subsequently identified the erectile dysfunction application could have developed it without competing with Pfizer’s patent protection.<\/p>\n\n\n\n

The lesson for abandoned patent analysis: always check original clinical trial data and adverse event reports for unexpected effects that may not have been commercially pursued by the original sponsor.<\/p>\n\n\n\n

Colchicine: Regulatory Strategy Meets Ancient Chemistry<\/h3>\n\n\n\n

Colchicine, derived from the autumn crocus plant, has been used medicinally for thousands of years. Its use for gout and pericarditis was well established in medical practice, and for decades it was sold in the U.S. without formal FDA approval as a “grandfathered” drug. It had no patent protection.<\/p>\n\n\n\n

URL Pharma (later acquired by Takeda) identified this situation and invested in clinical trials to formally study colchicine for FDA approval. They filed NDA applications under the 505(b)(2) pathway \u2014 which allows applicants to rely partly on existing published literature \u2014 and received FDA approval for Colcrys (colchicine for gout flares) in 2009. The FDA then required other unapproved colchicine products to be removed from the market.<\/p>\n\n\n\n

The result was that URL Pharma had FDA-approved market exclusivity for a drug that had been essentially free before, enabling them to raise prices dramatically. This created controversy \u2014 and eventually regulatory backlash \u2014 but it illustrates the power of regulatory exclusivity obtained through the 505(b)(2) pathway for previously abandoned or generic compounds.<\/p>\n\n\n\n

The strategy is replicable with appropriate risk management around the regulatory and public relations dimensions of pricing abandoned compounds.<\/p>\n\n\n\n

Small Molecule Revival in Kinase Inhibitor Space<\/h3>\n\n\n\n

The kinase inhibitor revolution in oncology beginning in the early 2000s (led by imatinib for CML) produced an enormous filing surge in kinase-related patents. Many of those filings covered broadly defined structural classes or kinase selectivity profiles that were subsequently abandoned as the field crowded and companies rationalized their pipelines.<\/p>\n\n\n\n

Multiple drug repositioning programs have successfully exploited this landscape. Academic research groups and small biotech companies have acquired or worked under freedom-to-operate from abandoned kinase inhibitor patents to develop compounds for rare cancers, autoimmune diseases, and inflammatory conditions where the original filer had no commercial interest.<\/p>\n\n\n\n

One illustrative class involves CDK (cyclin-dependent kinase) inhibitors originally developed for oncology indications where they failed. Several CDK inhibitors abandoned in oncology programs have since shown activity in neurodegeneration models \u2014 particularly for conditions involving tau pathology \u2014 and new academic and commercial programs have been established to exploit those signals without encountering the original IP. The original composition-of-matter patents had lapsed; the method-of-treatment for neurodegeneration wasn’t filed by the original owners; new IP could be established.<\/p>\n\n\n\n

The Generic Entry After Patent Lapse: A Routine Business Model<\/h3>\n\n\n\n

The most economically straightforward abandoned patent exploitation happens every day in the generic pharmaceutical industry. When a branded drug’s composition-of-matter patent expires (through running its 20-year term, not through abandonment, which is the more common terminal event), generic manufacturers file ANDAs and enter the market.<\/p>\n\n\n\n

But there are specific cases where generic entry is enabled by abandonment rather than expiration \u2014 situations where a branded manufacturer had filed continuation applications to extend effective protection but failed to maintain one or more family members, creating a hole in coverage.<\/p>\n\n\n\n

These “patent cliff accidents” are not theoretical. Pharmaceutical IP management across global operations is complex, and errors happen. Generic manufacturers retain dedicated IP surveillance teams specifically to identify these windows. The use of platforms like DrugPatentWatch \u2014 which monitors patent family status across jurisdictions and tracks Orange Book listings in real time \u2014 is standard practice among the largest generic companies precisely because these opportunities appear and close quickly.<\/p>\n\n\n\n

\n\n\n\n

Part Ten: Regulatory Considerations<\/h2>\n\n\n\n

The 505(b)(2) Pathway: Your Greatest Enabler<\/h3>\n\n\n\n

The FDA’s 505(b)(2) NDA pathway allows a new drug application to rely partly on published literature, prior FDA findings of safety and effectiveness for approved drugs, or other scientific data not developed by the applicant [18]. This pathway exists specifically to encourage drug development based on existing science.<\/p>\n\n\n\n

For abandoned drug patent exploitation, the 505(b)(2) pathway is transformative. Rather than generating a complete clinical data package from scratch (the cost center that makes standard drug development so expensive), a 505(b)(2) applicant can rely on the original sponsor’s published clinical data \u2014 Phase I safety data, pharmacokinetic profiles, dose-ranging studies \u2014 that became publicly available when the original program was terminated. The applicant then conducts only the clinical studies needed to demonstrate safety and efficacy for the new indication or new formulation.<\/p>\n\n\n\n

The result is a dramatically reduced clinical investment for a first-in-class or new-indication approval that comes with new data exclusivity. A 505(b)(2) approval grants three years of exclusivity if new clinical investigations are required, or five years if the application contains a new chemical entity. Combined with new method-of-treatment patents filed by the applicant, this creates a reconstituted IP and regulatory exclusivity stack protecting a product built on formerly abandoned IP.<\/p>\n\n\n\n

The economics are compelling. A 505(b)(2) development program for a repositioned compound with existing Phase I data might cost $30\u2013100 million in total clinical investment, compared to the $300\u2013500 million required for a conventional NDA supported by a full development program.<\/p>\n\n\n\n

Orphan Drug Designation: The Multiplier<\/h3>\n\n\n\n

The FDA’s Orphan Drug Act designates drugs for rare diseases affecting fewer than 200,000 people in the U.S. Orphan designation provides a package of benefits: seven years of market exclusivity after approval, 50% tax credit on qualified clinical trial costs, and eligibility for accelerated FDA review [19].<\/p>\n\n\n\n

For abandoned drug patent exploitation, orphan drug designation is worth examining for almost every candidate. Many compounds originally developed for common indications may have activity in rare disease subpopulations. A kinase inhibitor that failed in non-small cell lung cancer might have activity in a rare tumor histology affecting fewer than 200,000 patients annually \u2014 qualifying for orphan designation.<\/p>\n\n\n\n

The orphan designation can be filed before Phase III, and the seven-year market exclusivity runs from approval regardless of any underlying patent status. This means that an off-patent compound with no remaining IP protection can still generate market exclusivity if it obtains orphan designation for a qualifying rare disease indication. The exclusivity prevents the FDA from approving a competing orphan drug using the same compound for the same indication for seven years.<\/p>\n\n\n\n

The combination of 505(b)(2) NDA pathway, orphan drug designation, and new method-of-treatment patents can provide a fully reconstituted commercial protection framework for a compound whose original IP has completely lapsed.<\/p>\n\n\n\n

Data Exclusivity vs. Patent Protection: Understanding the Difference<\/h3>\n\n\n\n

Pharmaceutical commercialization is protected by two parallel systems that operate independently: patent law and regulatory exclusivity.<\/p>\n\n\n\n

Patent law is administered by the USPTO and the courts. It provides the right to exclude others from making, using, selling, importing, or offering for sale the claimed invention.<\/p>\n\n\n\n

Regulatory exclusivity is administered by the FDA. It restricts the FDA from approving a competitor application that relies on the original sponsor’s data, for a defined period. It does not prevent a competitor from developing a competing product independently; it only prevents the competitor from using a shortcut route that relies on the original data.<\/p>\n\n\n\n

The key point for abandoned patent analysis is that these two systems can be combined or can substitute for each other. A compound with no remaining patent protection may still have regulatory exclusivity protection. Conversely, a compound with active patent protection may have exhausted its data exclusivity periods. And a new development program on an off-patent compound can create new data exclusivity even in the absence of patent protection.<\/p>\n\n\n\n

Many opportunistic developers focus exclusively on patent status and fail to check regulatory exclusivity status. DrugPatentWatch’s product pages include regulatory exclusivity expiration dates alongside patent family information, which is why cross-referencing both databases before making investment decisions is important: a patent gap that appears to create commercial opportunity may be closed by unexpired data exclusivity.<\/p>\n\n\n\n

\n\n\n\n

Part Eleven: Deal Structures for Monetizing Abandoned IP<\/h2>\n\n\n\n

Outright Acquisition<\/h3>\n\n\n\n

The cleanest structure: you pay the original owner (or the original owner’s successor, or the bankruptcy estate, or the technology transfer office) for full title to the abandoned patent. You own it. You can develop it, license it, or hold it defensively.<\/p>\n\n\n\n

The challenge with outright acquisition is that abandoned patents, by definition, are no longer being actively managed by their owners. Finding the right counterparty requires investigative work: corporate successor searches, technology transfer office contacts at universities, searches of bankruptcy proceedings, state business registration checks to determine whether a lapsed startup is still a legal entity.<\/p>\n\n\n\n

Pricing for outright acquisition of abandoned pharmaceutical patents varies widely. A patent covering a compound with no active clinical interest and in a therapeutic area with no commercial activity might be acquired for $10,000 to $50,000 \u2014 essentially the cost of the legal work to execute the transfer plus a nominal amount recognizing the underlying IP. A patent covering a compound with recent positive clinical signals and proximity to a commercial market might command $500,000 to several million dollars, depending on how well-informed the seller is.<\/p>\n\n\n\n

The best deal opportunities arise when the seller is unaware of the commercial potential you have identified through your own research. This is where thorough diligence and a compelling read of the scientific and clinical data create genuine information advantage.<\/p>\n\n\n\n

Licensing Back to the Originator<\/h3>\n\n\n\n

In some cases, the original developer \u2014 the pharmaceutical company that abandoned the patent \u2014 may still have commercial interest in the compound through non-IP means. They may have retained manufacturing know-how, clinical relationships, or regulatory filings that make them the most logical commercializer.<\/p>\n\n\n\n

A strategy of acquiring an abandoned patent and then licensing it back to the originator seems counterintuitive, but it works when the originator has strategic reasons to have the program reactivated (perhaps a competitor’s success in an adjacent space changed the commercial calculus) and when the originator’s own administrative processes make it easier to acquire a license from a third party than to internally revive the program.<\/p>\n\n\n\n

This strategy also works as leverage in a broader deal: a party that acquires an abandoned patent with the intention of developing the compound can use the threat of independent development to create negotiating pressure for a reverse licensing deal at favorable economic terms.<\/p>\n\n\n\n

Joint Venture with a CRO or CDMO<\/h3>\n\n\n\n

For parties that have identified valuable abandoned IP but lack internal development capabilities, a joint venture with a contract research organization (CRO) or contract development and manufacturing organization (CDMO) can bridge the capability gap.<\/p>\n\n\n\n

The structure typically involves the IP owner contributing the patent rights and the CRO\/CDMO contributing development services in exchange for a share of future commercial value. The economic terms depend on the stage of development, the estimated cost of the required work, and the risk profile of the development program.<\/p>\n\n\n\n

This structure has become increasingly common as the specialized CRO sector has grown. Organizations like Evotec, Charles River, WuXi AppTec, and Parexel offer comprehensive services from discovery chemistry through clinical trial management, creating genuine end-to-end development partnership opportunities for IP holders who want to advance abandoned compounds without building an internal organization.<\/p>\n\n\n\n

Sublicensing to Emerging Markets<\/h3>\n\n\n\n

The geographic dimension of abandoned IP creates a specific deal structure: sublicensing rights to emerging market pharmaceutical manufacturers who need access to advanced pharmaceutical compounds and manufacturing processes for their local markets.<\/p>\n\n\n\n

An Indian generic company manufacturing for local sale, or a Brazilian manufacturer seeking to supply Latin American markets, may face a situation where they technically have freedom to operate (because the original patent was never filed or was abandoned in their jurisdiction) but are uncertain about manufacturing know-how, process IP, and regulatory strategy. A party that has assembled a comprehensive package of IP, process data, and regulatory guidance can license that package to emerging market manufacturers at a relatively low absolute price that still represents significant value.<\/p>\n\n\n\n

This structure is particularly relevant for compounds needed in low- and middle-income countries but priced out of reach under the branded company’s commercial model. The abandoned patent, combined with new manufacturing process improvements and regulatory filing assistance, becomes a global health asset with multiple monetization channels.<\/p>\n\n\n\n

\n\n\n\n

Part Twelve: Risk Management<\/h2>\n\n\n\n

Revival Risk: How to Assess It<\/h3>\n\n\n\n

Revival risk is the probability that the original patent owner revives the abandoned patent and asserts it against you. The practical assessment involves four questions.<\/p>\n\n\n\n

Is the original assignee still an operating entity? If the company that owned the patent is dissolved, merged into another entity with different strategic focus, or in bankruptcy, the probability of active management of any revival process is low.<\/p>\n\n\n\n

Is there an economic trigger for revival? The most likely revival scenario is one where the original owner discovers that you, or a competitor, are commercially exploiting the abandoned technology. If no commercial exploitation is occurring yet, there is less economic stimulus for revival action.<\/p>\n\n\n\n

How long has the abandonment persisted? USPTO revival petitions face heightened scrutiny for long lapses. A patent abandoned six months ago is more likely to be successfully revived than one abandoned five years ago. For truly ancient abandonments \u2014 those more than two years old \u2014 the practical revival risk is substantially lower.<\/p>\n\n\n\n

Does the original owner have counsel tracking the technology space? Large pharmaceutical companies with active IP departments monitor competitive developments in their technology areas. Small, dissolved companies do not. The company type matters.<\/p>\n\n\n\n

Prior Art Attacks: Protecting New IP You File<\/h3>\n\n\n\n

When you file new patents on new uses or improvements to an abandoned compound, your new IP is subject to invalidation challenges just like any other patent. Prior art that predates your filing can be raised in IPR proceedings, post-grant review, or litigation.<\/p>\n\n\n\n

The specific prior art risk for new-use patents on repositioned compounds is that the original clinical development program generated publications, conference abstracts, clinical trial registrations, and regulatory submissions that pre-date your new patent filing. If any of those public disclosures contain information that anticipates or renders obvious your new use claims, your new patents are vulnerable.<\/p>\n\n\n\n

Careful claim drafting that focuses on the specific new indication, patient subpopulation, dosing regimen, or biomarker selection can distinguish your new IP from the prior art landscape created by the original development program. This is a craft exercise requiring an experienced pharmaceutical patent attorney who understands both the prior art and the specific clinical proposition.<\/p>\n\n\n\n

Regulatory Risk: The FDA Has Discretion<\/h3>\n\n\n\n

Regulatory approval is not guaranteed even for compounds with strong clinical signals and FDA-approved precedents. The FDA can require additional safety studies, demand patient selection biomarker data, impose REMS requirements that limit commercial viability, or decline to accept the 505(b)(2) pathway for a specific application.<\/p>\n\n\n\n

The regulatory risk assessment for an abandoned compound differs from a standard new chemical entity in one important respect: there is often existing safety data, usually in the form of Phase I and II clinical data from the original program, that can either help or hurt. If the original program generated safety signals that the FDA is aware of, any new application will be reviewed with that history in mind. Clean prior safety data is a significant asset; concerning prior safety data is a significant obstacle.<\/p>\n\n\n\n

Early and direct engagement with the FDA \u2014 through pre-IND meetings, Type B meetings, and, where applicable, breakthrough therapy designation requests \u2014 is the most effective risk mitigation strategy. The FDA does not operate as a black box. Early dialogue can surface regulatory concerns before significant clinical investment is made.<\/p>\n\n\n\n

\n\n\n\n

Part Thirteen: Building an Abandoned Patent Pipeline<\/h2>\n\n\n\n

Systematic Monitoring Workflows<\/h3>\n\n\n\n

Single opportunistic deals are tactical. Systematic pipelines are strategic. Companies serious about abandoned patent exploitation build monitoring workflows that continuously scan for new opportunities rather than waiting for chance discoveries.<\/p>\n\n\n\n

The monitoring workflow has four components. The first is a patent database alert system \u2014 automated alerts configured in USPTO Patent Center, Espacenet, and PatentScope for new abandonments and lapse notices in defined technology classification codes. This requires ongoing configuration and review, but it ensures that new opportunities surface within weeks of the abandonment event rather than years later.<\/p>\n\n\n\n

The second component is a clinical trial database monitor. ClinicalTrials.gov sends email alerts for trials matching specified search terms. When a clinical trial for a compound of interest is terminated early or transitions to “completed” with negative results, the associated IP is a candidate for the abandonment pipeline.<\/p>\n\n\n\n

The third component is a corporate intelligence feed. M&A announcements, company bankruptcies, therapeutic area divestitures, and pipeline restructuring announcements all signal potential IP displacement. Services like BioPharma Catalyst, Evaluate Pharma, and Fierce Pharma Business produce daily news streams on corporate events in the pharmaceutical industry.<\/p>\n\n\n\n

The fourth component is a scientific literature monitor. Google Scholar and PubMed alerts for compounds of interest flag new scientific publications that may reveal activity not commercially pursued by the original patent holder \u2014 the kinase inhibitor with a new neurodegeneration paper, for example, or the failed antibacterial compound with a newly described antiviral mechanism.<\/p>\n\n\n\n

Internal Scoring Matrices<\/h3>\n\n\n\n

Once the monitoring workflow generates candidates, you need a systematic way to prioritize them. A scoring matrix that weights the following criteria produces objective comparisons:<\/p>\n\n\n\n

Commercial potential (0\u201340 points):<\/strong> Estimated market size for identified indication, competitive landscape, pricing comparables, time to market.<\/p>\n\n\n\n

IP quality (0\u201330 points):<\/strong> Scope of abandoned claims, quality of any new IP that can be filed, FTO clearance, revival risk assessment.<\/p>\n\n\n\n

Development risk (0\u201320 points):<\/strong> Stage of prior clinical development, quality of existing safety and efficacy data, regulatory pathway clarity, estimated development cost.<\/p>\n\n\n\n

Acquisition feasibility (0\u201310 points):<\/strong> Identifiability and accessibility of the IP owner, estimated acquisition or licensing cost, legal simplicity of the transaction.<\/p>\n\n\n\n

Candidates scoring above 70 out of 100 advance to formal due diligence. Those scoring 50\u201370 go into a watch list. Those below 50 are deprioritized.<\/p>\n\n\n\n

The matrix can be calibrated to the specific strategic objectives of the organization. A company focused on rare disease will weight orphan drug designation eligibility heavily. A generic company will weight time to ANDA filing heavily. A university technology transfer office will weight licensing feasibility and royalty potential.<\/p>\n\n\n\n

Partnering with IP Boutiques<\/h3>\n\n\n\n

Not all abandoned patent search and acquisition is done in-house. A growing ecosystem of IP boutique firms specializes in pharmaceutical patent analytics and abandoned patent transactions. Firms like Envision IP, RWS Group (NovumIP), and specialty divisions of large law firms like Finnegan, Henderson, Farabow, Garrett & Dunner offer contracted patent landscape analysis, abandoned patent identification, acquisition negotiation support, and licensing program development.<\/p>\n\n\n\n

For organizations without dedicated IP analytics resources, engaging a boutique firm on a project or retainer basis can accelerate the build-out of an abandoned patent pipeline without requiring full internal capability construction.<\/p>\n\n\n\n

The economics of boutique engagement typically involve an upfront project fee for the initial landscape analysis, plus a success fee or milestone payment tied to completed acquisitions. Some boutiques operate on a co-investment model, taking an equity stake in the opportunity in exchange for reduced upfront fees.<\/p>\n\n\n\n

\n\n\n\n

Part Thirteen-B: Patent Analytics Tools and the Competitive Intelligence Stack<\/h2>\n\n\n\n

Why Your Tool Selection Determines the Quality of Your Deals<\/h3>\n\n\n\n

Every abandoned patent opportunity begins with data. The quality of that data determines the quality of the opportunity, and the quality of the opportunity determines the quality of the returns. This is not a minor operational point. Operators who use inferior patent information tools systematically miss opportunities that better-equipped competitors find, and they fail to identify risks that better-equipped competitors avoid.<\/p>\n\n\n\n

The pharmaceutical patent analytics ecosystem has matured substantially over the past decade. What once required weeks of manual USPTO database searching now takes hours with modern purpose-built tools. That efficiency gain is available to everyone, which means the competitive advantage doesn’t come from access to the tools \u2014 it comes from the sophistication of the analytical questions you ask.<\/p>\n\n\n\n

Primary Database Resources<\/h3>\n\n\n\n

USPTO Patent Center<\/strong> is the authoritative primary source for U.S. prosecution status, fee payment history, and file wrapper documents. It is freely accessible and comprehensive. Its weaknesses are its non-intuitive interface, the absence of cross-referencing to pharmaceutical regulatory data, and the lack of analytics layers that allow bulk comparison across large patent populations. For individual patent deep dives, it is indispensable. For landscape-level scanning, it is clunky.<\/p>\n\n\n\n

Google Patents<\/strong> provides a more user-friendly interface for initial patent discovery and has excellent global coverage via partnerships with USPTO, EPO, and WIPO. Its classification-based filtering is serviceable for initial screening. It lacks the prosecution status detail and regulatory cross-referencing of specialist tools.<\/p>\n\n\n\n

Derwent Innovation<\/strong> (owned by Clarivate) is the industry-standard platform for large-scale pharmaceutical patent analysis. Its core advantage is the Derwent World Patents Index, which provides standardized, value-added abstracts for patents from 50+ patent authorities, normalized for easy cross-reference. Derwent’s family grouping algorithm is among the most accurate commercially available, which directly addresses the critical risk of missing active family members when analyzing apparently abandoned patents.<\/p>\n\n\n\n

Cortellis<\/strong> (also Clarivate) integrates patent data with clinical development data, regulatory approval records, and business intelligence, making it the closest thing to a single-platform solution for pharmaceutical competitive intelligence. It is expensive and positioned toward large enterprise users, but for organizations making multi-million-dollar decisions on abandoned IP, the integration value justifies the cost.<\/p>\n\n\n\n

DrugPatentWatch<\/strong> occupies a specific niche in this landscape: it focuses specifically on pharmaceutical products that have reached or are approaching the FDA approval stage, cross-referencing Orange Book listings, patent expiration data, and regulatory exclusivity timelines. For someone asking “when does the last active patent on Drug X expire, and what data exclusivity remains?” DrugPatentWatch answers that question faster and more completely than any combination of raw database searches. The platform’s monitoring alerts for expiring exclusivities and patent status changes are particularly valuable for business development teams tracking competitive patent landscapes on a rolling basis.<\/p>\n\n\n\n

The Role of AI in Patent Analysis<\/h3>\n\n\n\n

Machine learning tools for patent classification, prior art searching, and claim similarity analysis have improved substantially and are now integrated into most major patent analytics platforms. These tools accelerate the initial screening process but do not replace expert legal and scientific judgment for decision-making.<\/p>\n\n\n\n

The specific limitation of AI-assisted patent analysis in the abandoned drug patent context is that the most valuable analytical judgments \u2014 whether a compound’s clinical failure was scientifically inherent or context-specific, whether a claims amendment during prosecution materially narrowed the scope, whether a competitor’s patent would actually be asserted \u2014 require domain expertise that AI tools do not reliably provide. AI accelerates the search and filtering phases; human expertise is indispensable for the evaluation and decision phases.<\/p>\n\n\n\n

\n\n\n\n

Part Thirteen-C: International Dimensions of Abandoned Pharmaceutical Patents<\/h2>\n\n\n\n

The PCT System and National Phase Abandonments<\/h3>\n\n\n\n

The Patent Cooperation Treaty (PCT) allows an inventor to file a single international application and then elect to pursue national phase patents in individual countries within 30 months of the priority date. Large pharmaceutical companies routinely file PCT applications but then selectively enter national phase in only a subset of available countries based on commercial priorities.<\/p>\n\n\n\n

When a company decides not to pursue national phase entry in a given country \u2014 by failing to file the national phase application or pay the required fees within the deadline \u2014 the PCT application effectively lapse in that jurisdiction. The compound is free for use without a license in that country.<\/p>\n\n\n\n

This geographic abandonment pattern creates exploitable commercial corridors. A compound with active U.S. and EU patents but abandoned national-phase filings in Brazil, India, South Africa, and Southeast Asia can be manufactured and sold freely in those markets. If the compound is off-patent in major markets as well, the manufacturing can be done in low-cost jurisdictions and products exported globally to markets where no patent protection was obtained.<\/p>\n\n\n\n

Understanding where specific drugs are and are not patent-protected requires jurisdiction-by-jurisdiction analysis. DrugPatentWatch’s global patent coverage and tools like Minesoft’s Patent-Line provide international patent family status tracking that allows rapid identification of geographic patent gaps.<\/p>\n\n\n\n

The European Patent Office: Extended Validation Requirements<\/h3>\n\n\n\n

When a European patent is granted by the EPO, the patent holder must validate it in individual member states by paying national validation fees and, in some countries, providing a translation. Companies that fail to validate in specific states, or that fail to pay national renewal fees in subsequent years, lose protection in those states while potentially retaining protection in others.<\/p>\n\n\n\n

This creates a patchwork of protection within the EU that is invisible if you only check the EPO grant status. A drug covered by a European patent may have active protection in Germany, France, and the UK (post-Brexit, under the UK’s own system) while being completely unprotected in Spain, Italy, and Poland if the original patentee failed to validate or maintain rights in those countries.<\/p>\n\n\n\n

The practical research challenge is that you must check each national patent office’s records to determine validation status. Several commercial services \u2014 including Questel’s Orbit, Minesoft, and certain modules within Derwent Innovation \u2014 provide consolidated European national patent status tracking. This capability matters enormously for companies selling into multiple EU markets.<\/p>\n\n\n\n

The Unitary Patent system, which entered into force in June 2023 and covers 17 EU member states, simplifies future filings by allowing a single patent that covers all participating states automatically [21]. But the vast majority of currently relevant pharmaceutical patents predate the Unitary Patent system and remain under the old validation-by-country framework.<\/p>\n\n\n\n

India and Section 3(d): Evergreening Prevention<\/h3>\n\n\n\n

India’s Patents Act, Section 3(d), prevents the patenting of new forms (salts, esters, polymorphs) of known substances unless they demonstrate significantly enhanced efficacy compared to the known substance. This provision has made India one of the world’s most aggressive generic manufacturing jurisdictions and has produced a string of high-profile patent rejections for multinational pharmaceutical companies’ secondary patents.<\/p>\n\n\n\n

For abandoned patent analysis, India’s Section 3(d) is relevant in two ways. First, composition-of-matter patents on novel chemical entities are generally grantable in India (the Section 3(d) exclusion applies to modifications of known substances, not entirely new ones). Second, the type of secondary patents that often provide extended protection in U.S. and EU markets \u2014 polymorphic form patents, salt patents, prodrug patents \u2014 are frequently unavailable in India. This means that India’s effective patent-free window for generic entry often opens earlier than in Western markets, even when the original compound’s core IP is still active elsewhere.<\/p>\n\n\n\n

Compulsory Licensing as an Alternative Mechanism<\/h3>\n\n\n\n

Compulsory licensing is a distinct mechanism from patent abandonment but is worth understanding in the context of pharmaceutical IP access. Under TRIPS Article 31 and the Doha Declaration, member countries of the World Trade Organization can issue compulsory licenses allowing local manufacturers to produce patented pharmaceuticals without the patent holder’s consent under defined circumstances, including public health emergencies.<\/p>\n\n\n\n

India has issued compulsory licenses for pharmaceutical patents. Brazil, Thailand, and South Africa have all engaged in compulsory licensing for HIV medications. While compulsory licensing differs fundamentally from the voluntary exploitation of abandoned IP, it illustrates the broader international legal framework under which pharmaceutical IP is subject to public interest constraints \u2014 constraints that affect the commercial calculus for patented drugs in emerging markets and thus influence the commercial value of abandoned patents in those markets.<\/p>\n\n\n\n

\n\n\n\n

Part Thirteen-D: Tax Considerations and Deal Structuring<\/h2>\n\n\n\n

IP Holding Companies and Royalty Income<\/h3>\n\n\n\n

The tax treatment of income from pharmaceutical patent licensing and royalties has driven significant IP holding company structuring activity over the past two decades. Royalty income from patented pharmaceuticals has historically been taxable at ordinary income rates in most jurisdictions when received by operating companies, but various IP-box regimes \u2014 tax preferential treatment for income derived from intellectual property \u2014 were established in multiple European countries to attract IP registration.<\/p>\n\n\n\n

The Netherlands, Ireland, Luxembourg, and Switzerland all developed IP box regimes that offered reduced effective tax rates on royalty income and capital gains from IP sales. These regimes attracted significant pharmaceutical IP holding activity. U.S. tax reform under the Tax Cuts and Jobs Act of 2017 introduced a quasi-IP box incentive through the Foreign-Derived Intangible Income (FDII) deduction, partially counterbalancing some of the incentive to hold IP offshore.<\/p>\n\n\n\n

The practical implication for abandoned patent monetization is that the structure through which you hold and exploit pharmaceutical IP has meaningful tax consequences. An IP holding structure established in a favorable jurisdiction \u2014 reviewed by qualified international tax counsel \u2014 can substantially affect the after-tax returns on licensing or development income.<\/p>\n\n\n\n

This consideration is particularly relevant for parties aggregating multiple abandoned patent assets. A holding company structure that optimizes tax treatment across a portfolio of assets compounds the economic advantage at scale.<\/p>\n\n\n\n

Capital Allocation Timing<\/h3>\n\n\n\n

Pharmaceutical development is capital-intensive and has a long time horizon. Abandoned patent monetization programs that involve genuine drug development \u2014 filing 505(b)(2) NDAs, conducting Phase II trials, seeking FDA approval \u2014 require capital commitments that precede any commercial return by years.<\/p>\n\n\n\n

The discounted cash flow analysis discussed in the valuation section accounts for the time value of money, but the practical capital allocation challenge is matching the investment profile of the development program with the capital horizon of the investing entity. Venture capital funds with 10-year investment horizons can accommodate pharmaceutical development timelines. Hedge funds with shorter liquidity requirements generally cannot, which is why hedge fund involvement in pharmaceutical IP monetization tends to focus on late-stage assets or pure licensing plays rather than development programs.<\/p>\n\n\n\n

Royalty monetization structures \u2014 where an operating company sells future royalty streams from a licensed pharmaceutical asset to a royalty fund in exchange for upfront capital \u2014 have created a new class of pharmaceutical IP investor. Royalty funds like Royalty Pharma, DRI Healthcare, and Royalty Nexus acquire rights to future royalty streams from pharmaceutical assets, providing upfront capital to developers who would otherwise need to wait years to realize value. This structure can be applied to abandoned patent monetization programs where new IP has been filed and a licensing deal with a large pharmaceutical partner has been executed, converting the future royalty stream into present-value capital.<\/p>\n\n\n\n

\n\n\n\n

Part Thirteen-E: Practical Workflow \u2014 From Discovery to Deal Close<\/h2>\n\n\n\n

The 90-Day Diligence Sprint<\/h3>\n\n\n\n

For organizations serious about abandoned patent acquisition, a disciplined process with clear time gates prevents deals from stalling in indefinite evaluation and focuses resources on the highest-priority targets.<\/p>\n\n\n\n

A standard 90-day diligence sprint for an abandoned pharmaceutical patent target runs as follows.<\/p>\n\n\n\n

Days 1\u201314 (Initial Screening): Retrieve the prosecution history from USPTO Patent Center. Confirm abandonment status and date. Run a family search to identify related active applications. Run a DrugPatentWatch search on any drugs associated with the compound. Assess whether any active regulatory exclusivity blocks commercial exploitation. Produce a one-page screening memo with a preliminary score on the internal scoring matrix. Decision gate: advance to Phase II or deprioritize.<\/p>\n\n\n\n

Days 15\u201335 (Scientific Evaluation): Retrieve all public literature on the compound \u2014 preclinical, Phase I, Phase II publications and presentations, clinical trial registrations and results summaries. Commission a scientific assessment from a relevant therapeutic area expert. Determine whether clinical failure was science-driven or program-driven. Identify candidate new indications for repositioning. Produce a two-to-three-page scientific assessment memo. Decision gate: advance to legal analysis or deprioritize.<\/p>\n\n\n\n

Days 36\u201355 (Legal Analysis): Commission a full file wrapper review and prosecution history estoppel analysis from a pharmaceutical patent attorney. Conduct a freedom-to-operate analysis for the intended commercial activities. Assess revival risk based on the four-factor framework. Run a prior art search for any new use patents you intend to file. Produce a legal risk memo with a clear assessment of blocking risks and filing strategy. Decision gate: advance to deal structuring or deprioritize.<\/p>\n\n\n\n

Days 56\u201375 (Commercial Assessment): Build a commercial revenue model for the target indication(s). Identify analogous drug pricing and market penetration benchmarks. Calculate rNPV for the development program. Identify comparable transactions and produce a valuation range. Develop a deal structure proposal (outright acquisition, licensing, joint venture, or other). Decision gate: authorize negotiation or deprioritize.<\/p>\n\n\n\n

Days 76\u201390 (Negotiation and Close): Identify and contact the IP owner or their successor in interest. Negotiate the deal terms using the valuation range from the commercial assessment as the anchor. Engage transactional counsel to document the acquisition or license. Execute the transaction. File assignments with the USPTO and relevant international registries. Initiate new patent prosecution for identified new use patents.<\/p>\n\n\n\n

This 90-day framework is aggressive but achievable for a team with genuine expertise. It ensures that no deal languishes indefinitely in due diligence and that the organization maintains deal velocity needed to build a meaningful pipeline.<\/p>\n\n\n\n

Integration Into the Development Pipeline<\/h3>\n\n\n\n

Once an abandoned patent asset is acquired, the work shifts from deal-making to development execution. The asset needs to be integrated into the organization’s development portfolio management system with clearly defined milestones, resource requirements, and stage-gate decision criteria.<\/p>\n\n\n\n

The stage-gate system that governs standard pharmaceutical development applies equally to abandoned patent repositioning programs: proof-of-concept in vitro data, animal model efficacy, IND filing, Phase I safety confirmation, Phase II efficacy, Phase III outcome, NDA filing. Each gate requires a go\/no-go decision based on data, and each decision should be made by a governance committee with the authority to commit resources or terminate the program.<\/p>\n\n\n\n

Programs built on abandoned patents have one important structural difference from programs built on newly synthesized molecules: they enter the stage-gate process with existing data (however imperfect, and however old) that reduces early-stage uncertainty. That head start should be reflected in the program’s resource allocation and timeline projections.<\/p>\n\n\n\n

\n\n\n\n

Part Fourteen: The Ethics and Public Policy Dimension<\/h2>\n\n\n\n

When Exploitation Is Valuable vs. When It Extracts Rent<\/h3>\n\n\n\n

Honest analysis of abandoned pharmaceutical patent exploitation requires acknowledging the difference between genuinely value-creating activities and rent-extraction.<\/p>\n\n\n\n

Value creation occurs when an operator acquires abandoned IP, invests genuine resources in scientific and clinical development, and produces a drug that benefits patients who otherwise would not have had access to an effective treatment. The full colchicine story illustrates both poles: URL Pharma did invest in legitimate clinical trials, and the formal FDA approval process served patient safety purposes. The controversial element was the price increase for a drug that had been inexpensive and widely available for decades. The scientific value created was real; the pricing behavior was a different matter.<\/p>\n\n\n\n

Rent extraction occurs when an operator acquires abandoned IP for the sole purpose of extracting license fees from parties already practicing the technology, without contributing to scientific development or patient access. The NPE model in pharmaceuticals carries genuine public policy risks, particularly when used against generic manufacturers who have invested in manufacturing infrastructure based on a reasonable freedom-to-operate assumption.<\/p>\n\n\n\n

The distinction is not always clear-cut, and reasonable people disagree on where specific strategies fall. But operators with a long-term perspective should consider the regulatory and reputational risks associated with strategies that can be characterized as exploitative of the pharmaceutical patent system rather than genuinely additive to drug development.<\/p>\n\n\n\n

The Antimicrobial Resistance Opportunity (and Responsibility)<\/h3>\n\n\n\n

The abandoned IP landscape in antibiotics is uniquely large and uniquely important from a public health standpoint. Antimicrobial resistance (AMR) kills approximately 700,000 people annually worldwide, a figure projected to reach 10 million by 2050 under current trajectories according to the O’Neill Commission Report on Antimicrobial Resistance [20].<\/p>\n\n\n\n

The antibiotic pipeline has been largely abandoned by major pharmaceutical companies because the economics are unfavorable: antibiotics are used for short courses, prescribers are incentivized to use existing agents first to preserve efficacy of new ones, and prices are suppressed by payer resistance. The result is a massive inventory of abandoned antibiotic research IP and a genuine public health crisis.<\/p>\n\n\n\n

Operators who can find ways to commercialize abandoned antibiotic IP through creative business models \u2014 subscription-based payment, pull incentive programs, government procurement arrangements, and global health partnerships \u2014 are simultaneously addressing one of the most significant public health challenges of the century and building a business with relatively limited commercial competition.<\/p>\n\n\n\n

The PASTEUR Act in the United States, the AMR Action Fund, and various international initiatives are creating new funding mechanisms specifically designed to improve the economics of antibiotic development. An operator who builds a pipeline of abandoned antibiotic IP may be positioned to benefit from these mechanisms as they mature.<\/p>\n\n\n\n

\n\n\n\n

Part Fifteen: The Information Advantage<\/h2>\n\n\n\n

Why Most Competitors Miss These Opportunities<\/h3>\n\n\n\n

The opportunity in abandoned pharmaceutical patents persists partly because the information required to identify and act on it is fragmented across multiple databases, requires specialized legal and scientific interpretation, and lives in a format that is genuinely hostile to fast analysis.<\/p>\n\n\n\n

Business development professionals at pharmaceutical companies are evaluated on deal flow with known assets \u2014 approved drugs, late-stage pipeline candidates, technologies with readily legible value. Abandoned IP is invisible in those deal databases. It doesn’t appear in broker lists. There is no investment banker calling to pitch a lapsed patent portfolio.<\/p>\n\n\n\n

Investors in pharmaceutical assets similarly focus on the conventional pipeline development path. A venture fund looking for a Series A biotech deal wants to see a company with an identified asset, validated biology, and a clear development path. A company built on abandoned IP identified through systematic database analysis looks unusual in that context, even when the underlying opportunity is excellent.<\/p>\n\n\n\n

The information advantage available to operators who invest in systematic abandoned patent analysis is real and durable precisely because the opportunity requires work that most market participants are not structured to do.<\/p>\n\n\n\n

Building the Capability<\/h3>\n\n\n\n

The capability required to exploit abandoned pharmaceutical patents systematically is a combination of patent database proficiency, pharmaceutical science literacy, regulatory strategy knowledge, and transactional deal-making skill. Very few individuals have all four. Effective teams bring these capabilities together.<\/p>\n\n\n\n

Patent analysis capability can be sourced from experienced patent agents or licensed patent professionals with pharmaceutical backgrounds. Scientific evaluation requires pharmaceutical scientists or physicians with relevant therapeutic area expertise. Regulatory strategy needs a professional who has worked in or closely with the FDA and understands the 505(b)(2) pathway mechanics. Deal-making can come from pharmaceutical business development professionals or experienced pharmaceutical IP attorneys.<\/p>\n\n\n\n

The team does not need to be large. A four-to-six-person unit with genuine deep expertise in each domain can run a systematic abandoned patent exploitation program that generates a pipeline of development or licensing opportunities. The marginal cost of adding a new opportunity to a running pipeline is low once the monitoring infrastructure and evaluation framework are in place.<\/p>\n\n\n\n

\n\n\n\n

Conclusion<\/h2>\n\n\n\n

The case for systematic abandoned pharmaceutical patent exploitation rests on two straightforward observations.<\/p>\n\n\n\n

First, pharmaceutical patents are abandoned at high rates for reasons that often have nothing to do with the intrinsic value of the underlying science. Capital constraints, corporate strategy changes, pipeline competition, and administrative failures collectively produce a continuous flow of lapsed and abandoned IP covering molecules, formulations, and methods that were once considered valuable enough to protect.<\/p>\n\n\n\n

Second, the information required to identify and act on these opportunities is available in public databases but requires meaningful expertise to interpret. That expertise gap is the source of the competitive advantage available to operators who build it.<\/p>\n\n\n\n

The regulatory toolkit \u2014 particularly the 505(b)(2) NDA pathway, orphan drug designation, and the various forms of regulatory exclusivity available to new development programs \u2014 allows operators to reconstitute meaningful commercial protection around off-patent compounds. The legal tools \u2014 intervening rights, careful FTO analysis, continuation family diligence \u2014 allow them to manage the legal risks that make inexperienced operators hesitate.<\/p>\n\n\n\n

Platforms like DrugPatentWatch reduce the information cost of identifying and evaluating pharmaceutical patent status by aggregating patent, regulatory exclusivity, and litigation data in one accessible interface. They are not a substitute for legal and scientific judgment, but they dramatically compress the time required to develop an informed view of the IP and regulatory landscape for any given compound.<\/p>\n\n\n\n

The operators who have built businesses on this model \u2014 Celgene’s immunomodulatory drug franchise, URL Pharma’s regulatory strategy for colchicine, the generic manufacturers who routinely monitor patent family lapses for entry opportunities \u2014 have collectively demonstrated that abandoned pharmaceutical IP is a genuine, recurring, and exploitable commercial opportunity.<\/p>\n\n\n\n

The inventory replenishes itself every year, because pharmaceutical development is hard, capital is scarce, and corporate strategies change. The opportunity will be here long after this article is read.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/h2>\n\n\n\n

Abandonment is not failure.<\/strong> A pharmaceutical patent can be abandoned for administrative, strategic, or financial reasons that have nothing to do with whether the underlying compound has biological or commercial value. Evaluate the science independently of the IP status.<\/p>\n\n\n\n

The layered protection structure matters.<\/strong> Patent expiration or abandonment does not automatically create commercial freedom. Regulatory data exclusivity, orphan drug market exclusivity, and other non-patent barriers may remain active. Always check both layers.<\/p>\n\n\n\n

File wrapper analysis is non-negotiable.<\/strong> Reading the prosecution history tells you what the claims actually cover (after prosecution history estoppel), why the patent was abandoned, and what risk of revival exists. Skipping this step is expensive.<\/p>\n\n\n\n

The 505(b)(2) pathway is the single most powerful regulatory tool<\/strong> for abandoned drug patent monetization. It allows development of new indications or new formulations at significantly reduced clinical investment by relying on existing published data.<\/p>\n\n\n\n

Systematic pipelines outperform opportunistic deals.<\/strong> Building monitoring workflows that continuously identify new abandonments in defined technology areas creates sustainable competitive advantage. Single-deal opportunism does not.<\/p>\n\n\n\n

Revival risk is manageable but real.<\/strong> Conduct revival risk assessment as part of every due diligence. Understand the intervening rights doctrine. Don’t assume legal risk doesn’t exist simply because the USPTO system shows “abandoned” status.<\/p>\n\n\n\n

Orphan drug designation can restore seven years of market exclusivity<\/strong> to a compound that has lost all patent protection, when a qualifying rare disease indication can be identified. This deserves specific attention in every repositioning diligence process.<\/p>\n\n\n\n

Geographic arbitrage exists and is under-exploited.<\/strong> PCT national phase abandonments in emerging markets create freedom-to-operate specifically in those jurisdictions. The full international family analysis opens commercial channels not visible from U.S.-only patent searching.<\/p>\n\n\n\n

\n\n\n\n

FAQ<\/h2>\n\n\n\n

Q1: Can an abandoned patent be asserted against me after I begin commercial activities?<\/strong><\/p>\n\n\n\n

Yes, under specific conditions. The most significant risk is “unintentional abandonment” revival under 37 C.F.R. \u00a7 1.137. If the original owner revives a lapsed patent after you have begun commercial activities, you may have intervening rights under 35 U.S.C. \u00a7 41(c)(2) that protect activities that occurred during the lapse period and allow you to continue those specific activities. However, the intervening rights doctrine does not protect new commercial activities you commence after the revival, and it does not prevent the revived patent from being asserted against other parties. A thorough revival risk assessment \u2014 evaluating the age of the abandonment, the status of the original assignee, and the economic triggers that might prompt revival \u2014 is essential before making significant commercial investments.<\/p>\n\n\n\n

Q2: How do I distinguish between a patent that was abandoned because of genuine scientific failure versus administrative accident?<\/strong><\/p>\n\n\n\n

The file wrapper tells the story. If the abandonment was due to a missed deadline in responding to an office action, you will see a Notice of Abandonment citing failure to respond, without any substantive examiner rejection on the merits. If the abandonment followed repeated rejections on prior art or obviousness grounds, those rejections will be in the record, and you can evaluate whether they would have prevented issuance of any claims with commercial value. For post-issuance lapses (maintenance fee nonpayment), the abandonment is always administrative in the narrow sense, but a pharmaceutical scientist’s review of the clinical data associated with the compound will tell you whether the decision to stop paying was scientifically justified or simply a corporate resource allocation decision.<\/p>\n\n\n\n

Q3: What role does DrugPatentWatch play in the research process compared to raw USPTO database searches?<\/strong><\/p>\n\n\n\n

The USPTO Patent Center provides authoritative prosecution status information on individual patents and applications, but it does not cross-reference the regulatory landscape \u2014 Orange Book listings, data exclusivity expiration dates, REMS requirements, litigation history \u2014 that determines whether commercial freedom exists beyond the patent itself. DrugPatentWatch specifically aggregates these pharmaceutical-specific data layers for approved drugs and their associated IP, allowing analysts to quickly map the full commercial protection picture without manually cross-referencing multiple federal databases. For broad landscape analysis across large numbers of compounds, tools like Derwent Innovation or PatSnap are more appropriate; DrugPatentWatch is particularly valuable for deep-dive analysis of specific approved or formerly approved drugs where the full IP-regulatory interaction matters.<\/p>\n\n\n\n

Q4: Is the 505(b)(2) pathway available for every repositioned off-patent compound, or are there restrictions?<\/strong><\/p>\n\n\n\n

The 505(b)(2) pathway is available for any NDA that relies at least partly on data not developed by the applicant \u2014 including published literature, prior FDA findings of safety and effectiveness, or the applicant’s own investigations combined with published data. It is not restricted to repositioned compounds; it covers new formulations, new routes of administration, new dosing regimens, and new combinations of approved drugs as well. The key restriction is that the pathway requires a genuine NDA submission, not an ANDA. The applicant must demonstrate that the proposed drug is safe and effective for the proposed use; it cannot be approved through bioequivalence alone. If the repositioning involves a truly new indication with no prior approval, the 505(b)(2) applicant must provide adequate clinical evidence of efficacy in that indication, though Phase II data may be sufficient for some applications (particularly with breakthrough therapy designation).<\/p>\n\n\n\n

Q5: How does the Hatch-Waxman Act’s patent certification system interact with abandoned patents?<\/strong><\/p>\n\n\n\n

Under Hatch-Waxman, a generic ANDA applicant must certify the status of each patent listed in the FDA Orange Book for the referenced drug. A Paragraph IV certification asserts that a listed patent is invalid or will not be infringed by the generic product, which triggers the 30-month stay provision and often generates patent infringement litigation. If a patent has been abandoned or has expired and is therefore no longer listed in the Orange Book, there is no Paragraph IV certification requirement for that patent. This is the central operational meaning of Orange Book patent expiration for generic market entry: when the last relevant Orange Book patent expires or is removed, generic manufacturers can file ANDAs without triggering the stay provision (though any remaining data exclusivity still governs the FDA’s ability to approve the ANDA). For abandoned composition-of-matter patents that were never Orange Book listed (because the drug was never approved, or because the patent was abandoned before or during development), the Hatch-Waxman mechanism is not directly applicable, and freedom to operate is governed purely by the patent law analysis.<\/p>\n\n\n\n

\n\n\n\n

References<\/h2>\n\n\n\n

[1] United States Patent and Trademark Office. (2023). USPTO Performance and Accountability Report FY 2023<\/em>. U.S. Department of Commerce. https:\/\/www.uspto.gov\/about-us\/performance-and-planning\/uspto-annual-reports<\/p>\n\n\n\n

[2] United States Patent and Trademark Office. (2024). Patent fee schedule<\/em>. https:\/\/www.uspto.gov\/learning-and-resources\/fees-and-payment\/uspto-fee-schedule<\/p>\n\n\n\n

[3] World Intellectual Property Organization. (2023). World Intellectual Property Indicators 2023<\/em>. WIPO. https:\/\/www.wipo.int\/edocs\/pubdocs\/en\/wipo-pub-941-2023-en-world-intellectual-property-indicators-2023.pdf<\/p>\n\n\n\n

[4] Carley, M., & Hegde, D. (2020). Are patent applications abandoned strategically? Research Policy<\/em>, 49(3), 103926. https:\/\/doi.org\/10.1016\/j.respol.2019.103926<\/p>\n\n\n\n

[5] Sampat, B. N., & Shadlen, K. C. (2017). The effects of TRIPS implementation on access to medicines in low- and middle-income countries. Nature Biotechnology<\/em>, 35(5), 422\u2013427. https:\/\/doi.org\/10.1038\/nbt.3832<\/p>\n\n\n\n

[6] Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014). Clinical development success rates for investigational drugs. Nature Biotechnology<\/em>, 32(1), 40\u201351. https:\/\/doi.org\/10.1038\/nbt.2786<\/p>\n\n\n\n

[7] 35 U.S.C. \u00a7 41(c)(2). Patent fees; patent and trademark search systems. United States Code.<\/p>\n\n\n\n

[8] 37 C.F.R. \u00a7 1.137. Revival of abandoned application, or terminated or limited reexamination prosecution. Code of Federal Regulations.<\/p>\n\n\n\n

[9] Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act), Pub. L. No. 98-417, 98 Stat. 1585 (1984).<\/p>\n\n\n\n

[10] IQVIA Institute for Human Data Science. (2022). The use of medicines in the U.S. 2022<\/em>. IQVIA. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/the-use-of-medicines-in-the-us-2022<\/p>\n\n\n\n

[11] Tufts Center for the Study of Drug Development. (2018). Cost and cycle time for drug repositioning<\/em>. Tufts University.<\/p>\n\n\n\n

[12] Alice Corp. Pty. Ltd. v. CLS Bank International<\/em>, 573 U.S. 208 (2014).<\/p>\n\n\n\n

[13] United States Patent and Trademark Office. (2023). Trial statistics: IPR, PGR, CBM \u2014 Patent Trial and Appeal Board<\/em>. https:\/\/www.uspto.gov\/patents\/ptab\/statistics<\/p>\n\n\n\n

[14] Stewart, J. J., Allison, P. N., & Johnson, R. S. (2001). Putting a price on biotechnology. Nature Biotechnology<\/em>, 19(9), 813\u2013817. https:\/\/doi.org\/10.1038\/nbt0901-813<\/p>\n\n\n\n

[15] Razgaitis, R. (2009). Valuation and dealmaking of technology-based intellectual property: Principles, methods and tools<\/em> (2nd ed.). John Wiley & Sons.<\/p>\n\n\n\n

[16] Wong, C. H., Siah, K. W., & Lo, A. W. (2019). Estimation of clinical trial success rates and related parameters. Biostatistics<\/em>, 20(2), 273\u2013286. https:\/\/doi.org\/10.1093\/biostatistics\/kxx069<\/p>\n\n\n\n

[17] Tufts Center for the Study of Drug Development. (2016). Cost of developing a new drug<\/em>. Tufts University. http:\/\/csdd.tufts.edu\/news\/complete_story\/pr_tufts_csdd_2014_cost_study<\/p>\n\n\n\n

[18] Food and Drug Administration. (2004). Guidance for industry: Applications covered by section 505(b)(2)<\/em>. U.S. Department of Health and Human Services. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents<\/p>\n\n\n\n

[19] Orphan Drug Act, Pub. L. No. 97-414, 96 Stat. 2049 (1983). Codified at 21 U.S.C. \u00a7 360aa et seq.<\/p>\n\n\n\n

[20] O’Neill, J. (2016). Tackling drug-resistant infections globally: Final report and recommendations \u2014 The review on antimicrobial resistance<\/em>. Wellcome Trust and HM Government. https:\/\/amr-review.org\/sites\/default\/files\/160525_Final%20paper_with%20cover.pdf<\/p>\n\n\n\n

[21] European Patent Office. (2023). The unitary patent system<\/em>. https:\/\/www.epo.org\/applying\/european\/unitary.html<\/p>\n","protected":false},"excerpt":{"rendered":"

Introduction: The Graveyard With a Pulse Every year, thousands of pharmaceutical patents die quietly. No press release. No analyst call. […]<\/p>\n","protected":false},"author":1,"featured_media":36815,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-36814","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/36814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=36814"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/36814\/revisions"}],"predecessor-version":[{"id":36816,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/36814\/revisions\/36816"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/36815"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=36814"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=36814"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=36814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}